Prostanoid and isoprostanoid pathways in atherogenesis

Atherosclerosis

Volumn 201, Issue 1, 2008, Pages 8-16

  Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Inflammation; Oxidative stress; Prostaglandin

Indexed keywords

ARACHIDONIC ACID; ISOPROSTANE DERIVATIVE; ISOPROSTANOID DERIVATIVE; MEMBRANE LIPID; MEMBRANE PHOSPHOLIPID; PHOSPHOLIPID; PROSTACYCLIN; PROSTANOID; THROMBOXANE A2; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; ESTERIFICATION; FATTY ACID OXIDATION; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; F2-ISOPROSTANES; HUMANS; LIPID PEROXIDATION; OXIDATIVE STRESS; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; THROMBOXANE A2;

EID: 54049129639     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.04.037     Document Type: Review

References (82)

1. Aschoff L. In: Cowdry E.V. (Ed). Arteriosclerosis: a survey of problem (1933), MacMillan, New York 1-18
2. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
3. Vakkilainen J., Steiner G., and Ansauer J.C. Relationships between low density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107 (2003) 1733-1737
4. Wallace C., Newhouse S.J., Braund P.., et al. Genome-wide association study indentifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 82 (2008) 139-149
5. Boudjeltia K.Z., Guillaume M., Henuzet C., et al. Fibrinolysis and cardiovascular risk factors: association with fibrinogen, lipids, and monocyte count. Eur J Inter Med 17 (2006) 102-108
6. Gatto N.M., Hodis H.N., Liu C.-R., et al. Brachial artery vasoreactivity is associated with cross-sectional and longitudinal anatomical measures of atherosclerosis in post-menopausal women with coronary artery disease. Atherosclerosis 196 (2008) 674-681
7. Ingelsson E., Pencina M.J., Tofler G.H., et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. The Framingham Offspring Study. Circulation 116 (2007) 984-992
8. Fibrinogen Study Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. An individual participant meta-analysis. JAMA 294 (2005) 1799-1809
9. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
10. Dogne J.M., Hanson J., and Praticò D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 26 (2005) 639-644
11. Simmons D.L., Botting R.M., and Hla T. Cycloxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56 (2004) 387-437
12. Smith W.L., Garavito R.M., and de Witt D.L. Prostaglandin endoperoxide H synthase (cyclooxygenases)-1 and -2. J Biol Chem 271 (1996) 33157-33160
13. Chandrasekharan N.V., Dai H., Roos L., et al. Cox-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 99 (2002) 13926-13931
14. Kis B., Snipes A., Bari F., and Busija D.W. Regional distribution of cyclooxygenase-3 mRNA in the rat central nervous system. Brain Res Mol Brain Res 126 (2004) 78-80
15. Shaftel S.S., Olschowka J.A., Hurley S.D., et al. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res Mol Brain Res 119 (2003) 213-215
16. Qin N., Zhang S.P., Reitz T.L., et al. Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther 315 (2005) 1298-1305
17. Kis B., Snipes J.A., Gaspar T., et al. Cloning of cyclooxygenase-1b (putative COX-3) in mouse. Inflamm Res 55 (2006) 274-278
18. Kujubu D.A., Fletcher B.S., Varnum B.C., et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266 (1991) 12866-12872
19. Seibert M., Zhang Y., Leahy K., et al. Pharmacological and biochemical demonstration of the role of cylcooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91 (1994) 12013-12017
20. Inoue I., Taba Y., Miwa C., et al. Transcriptional and posttranslational regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscl Thromb Vasc Biol 22 (2002) 1415-1420
21. Khan K.N., Stanfield K.M., Harris R.K., and Baron D.A. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 23 (2001) 321-330
22. Yaksh T.L., Dirig D.M., and Conway C.M. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 21 (2001) 5847-5853
23. Dogne J.M., de Leval X., Hanson J., et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 11 (2004) 1233-1241
24. de Leval X., Hanson J., David L.J., et al. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem 11 (2004) 1243-1252
25. Moncada S., Higgs J., and Vane J.R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1 (1977) 18-20
26. Moncada S., Gryglewski R., Bunting S., et al. An enzyme isolated from arteries transform prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 (1976) 663-665
27. Cyrus T., Yao Y., Rokach J., et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor deficient mice. Circulation 106 (2002) 1282-1287
28. Belton O., Byrne D., Kearney D., et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
29. Katugampola S.D., and Davenport A.P. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartan. Br J Pharmacol 134 (2001) 1385-1392
30. 2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells. Eur J Pharmacol 312 (1996) 367-377
31. Spagnuolo P.J., Ellner J.J., Hassid A., and Dunn M.J. Mediation of augmented monocyte adhesiveness by thromboxane. Inflammation 12 (1988) 1-9
32. Tzoulaki I., Murray G.D., Lee A.J., et al. C-reactive protein, interleukin-6, and soluble adhesion molecules predictors of progressive peripheral atherosclerosis in the general population: Edinburg Artery Study. Circulation 112 (2005) 976-983
33. Bayat H., Xu S., Pimentel D., Cohen R.A., and Jiang B. Activation of thromboxane receptor upregulates interleukin (IL) -1β-induced VCAM-1 expression through JNK signal. Arterioscl Thromb Vasc Biol 28 (2008) 127-134
34. 2 receptor expression by lipid soluble smoking particles through post-transcriptional mechanisms. Atherosclerosis 196 2 (2008) 608-616
35. Bailey J.M., and Butter J. Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation. Atherosclerosis 17 (1973) 515-522
36. Paul A., Calleja L., Camps J., et al. The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci 68 (2000) 457-465
37. Praticò D., Tillmann C., Zhang Z.B., et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98 (2001) 3358-3363
38. Belton O., Duffy A., Toomey S., and Fitzgerald D.J. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108 (2003) 3017-3023
39. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324 (2002) 71-86
40. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
41. Metz J., Wolf O., Schmelz A., Pill J., Stegmeier K.H., and Hartig F. Atherosclerosis in the aorta of hypercholesterolemic rabbits and the influence of daltroban. Exp Pathol 41 (1991) 57-69
42. Cayatte A.J., Du Y., Olivier-Krazinski J., et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscl Thromb Vasc Biol 20 (2000) 1724-1728
43. Viles-Gonzales J.F., Fuster V., Corti R., et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 26 (2005) 1557-1561
44. Worth N.F., Berry C.L., Thomas A.C., and Campbell J.H. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 183 (2005) 65-73
45. Vilahur G., Casani L., and Badimon L. A thromboxane A2/prostgalndin H2-receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 98 (2007) 662-669
46. Cyrus T., Yao Y., Ding T., Dogne J.M., and Praticò D. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur J Pharmacol 561 (2007) 105-111
47. 2 suppression in LDL r KO mice. Blood 109 (2007) 3291-3296
48. Praticò D., Cyrus T., Li H., and FitzGerald G.A. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 96 (2000) 3823-3826
49. Dogne J.M., Hanson J., Supuran C., and Praticó D. Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des 12 (2006) 971-975
50. Cheng Y., Wang M., Yu Y., et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116 (2006) 1391-1399
51. Hennan J.K., Huamng J., Barret T.D., et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104 (2001) 820-825
52. Zewde T., and Mattson D.L. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 44 (2004) 424-428
53. Pidgeon G.P., Tamosiuniene R., Chen G., et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 110 (2004) 2701-2707
54. Murata T., Ushikubi F., Matsuoka T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 (1997) 678-682
55. Burleigh M.E., Babaev V.R., Oates J.A., et al. Cycloxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816-1823
56. Rott D., Zhu J., Burnett M.S., et al. Effects of MF-tricyclic, a selective cycloxygenase-2 inhibitor, on atherogenesis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 41 (2003) 1812-1819
57. Bea F., Blessing E., Bennett B.J., et al. Chronic inhibition of cycloxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 60 (2003) 198-204
58. Olensen M., Kwong E., Meztli A., et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J 36 (2002) 362-367
59. Metzner J., Popp L., Marian C., et al. The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in apoE-/- mice. J Mol Med 85 (2007) 623-633
60. 2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 147 (1999) 1-10
61. Praticò D., Lawson J.A., Rokach J., et al. The isoprostanes in biology and medicine. Trends Endocrinol Metab 12 (2001) 243-247
62. 2α by human monocytes: discriminant production by reactive oxygen species and PG G/H S-2. J Biol Chem 271 (1996) 8919-8924
63. Steinberg D., and Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis?. Circulation 105 (2002) 2107-2111
64. Witztum J.L., and Berliner J.A. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol 9 (1998) 441-448
65. Hansson G.K. Inflammation, atherosclerosis and coronary artery disease. New Engl J Med 352 (2005) 1685-1695
66. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100 (1997) 2028-2034
67. Praticò D. Lipid peroxidation in mouse models of atherosclerosis. Trends Cardiovasc Med 11 (2001) 112-116
68. 2-alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
69. 2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 37 (2001) 76-80
70. Cipollone F., Ciabattoni G., Patrignani P., et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102 (2000) 1007-1013
71. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 103 (1999) 421-427
72. Praticò D., Tangirala R., Rader D.J., et al. Vitamin E suppresses isoprostanes generation in vivo and reduces atherogenesis in ApoE-deficient mice. Nat Med 4 (1998) 1189-1192
73. Cyrus T., Yao Y., Rokach J., et al. Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions. Circulation 107 (2003) 521-523
74. Terasawa Y., Ladha Z., Leonard S.W., et al. Increased atherosclerosis in hyperlipidemic mice deficient in α-tocopherol transfer protein and vitamin E. Proc Natl Acad Sci USA 97 (2000) 13830-13834
75. 2α as a risk marker in patients with coronary heart disease. Circulation 109 (2004) 843-848
76. 2-isoprostanes are not just markers of oxidative stress. Free Radic Biol Med 44 3 (2008) 247-256
77. 2α. J Biol Chem 271 (1996) 14916-14924
78. 2α-III. Evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 112 (2005) 2867-2874
79. 2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 41 (2003) 1198-1204
80. Shih D.M., Xia Y.R., Wang X.P., et al. Combined serum paroxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275 (2000) 15735-17527
81. Cyrus T., Witztum J.L., Rader D.J., et al. Disruption of 12/15 LO-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 103 (1999) 1597-1604
82. Tang L, Ding T, Praticò D. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15 lipoxygenase gene disruption in apolipoprotein E deficient mice. Atherosclerosis 2008; Jan 17 [Epub ahead of print].